Avastin (bevacizumab), a monoclonal antibody that inhibits the vascular endothelial growth factor and prevents the growth of blood vessels (angiogenesis), has received FDA approval to treat patients with persistent or late-stage cervical cancer.1 The approval allows administration of bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan in the said population.2
The phase 3 study, conducted in 452 women, met its primary end point of improved overall survival (OS), with a significant 26% reduction in the risk of death when bevacizumab was combined with chemotherapy, compared with chemotherapy alone (median OS:16.8 months vs 12.9 months; hazard ratio = 0.74; P =.0132). Additionally, inclusion of bevacizumab resulted in a higher rate of tumor shrinkage compared with chemotherapy alone.2
Avastin, approved in 2004 as first-line treatment for patients with metastatic colorectal cancer, was the first angiogenesis inhibitor to be granted FDA authorization.3 Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said, “Avastin is the first drug approved for patients with late-stage cervical cancer since the 2006 approval of topotecan with cisplatin. It is also the first biologic agent approved for patients with late-stage cervical cancer and was approved in less than 4 months under the FDA’s priority review program.”1
EBO
Some of the treatment-related side effects of Avastin include hypertension, thrombosis, and gastrointestinal-vaginal fistulas.2 References
1. FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer [press release]. Silver Spring, MD: FDA; August 14, 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm410121.htm.
2. FDA approves Genentech’s Avastin plus chemotherapy for treatment of advanced cervical cancer [press release]. South San Francisco, CA: Genentech; August 14, 2014.
http://www.gene.com/media/press-releases/14571/2014-08-14/fda-approves-genentechs-avastin-plus-che.
3. FDA approves first angiogenesis inhibitor to treat colorectal cancer [press release]. Silver Spring, MD: FDA; February 26, 2004. http:// www.fda.gov/newsevents/newsroom/pressannouncements/ 2004/ucm108252.htm.
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More